IL304005A - Methods for the preparation of AZADECALIN fused heteroaryl-ketone glucocorticoid receptor modulators - Google Patents

Methods for the preparation of AZADECALIN fused heteroaryl-ketone glucocorticoid receptor modulators

Info

Publication number
IL304005A
IL304005A IL304005A IL30400523A IL304005A IL 304005 A IL304005 A IL 304005A IL 304005 A IL304005 A IL 304005A IL 30400523 A IL30400523 A IL 30400523A IL 304005 A IL304005 A IL 304005A
Authority
IL
Israel
Prior art keywords
compound
formula
amount
less
methyl
Prior art date
Application number
IL304005A
Other languages
English (en)
Hebrew (he)
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of IL304005A publication Critical patent/IL304005A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL304005A 2020-12-25 2021-12-22 Methods for the preparation of AZADECALIN fused heteroaryl-ketone glucocorticoid receptor modulators IL304005A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/139524 WO2022134033A1 (en) 2020-12-25 2020-12-25 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PCT/US2021/064947 WO2022140600A1 (en) 2020-12-25 2021-12-22 Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (1)

Publication Number Publication Date
IL304005A true IL304005A (en) 2023-08-01

Family

ID=82157262

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304005A IL304005A (en) 2020-12-25 2021-12-22 Methods for the preparation of AZADECALIN fused heteroaryl-ketone glucocorticoid receptor modulators

Country Status (10)

Country Link
US (2) US12152028B2 (cg-RX-API-DMAC7.html)
EP (1) EP4267577A4 (cg-RX-API-DMAC7.html)
JP (1) JP7720914B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230124985A (cg-RX-API-DMAC7.html)
CN (1) CN116867780A (cg-RX-API-DMAC7.html)
AU (2) AU2021410756B2 (cg-RX-API-DMAC7.html)
CA (1) CA3202354A1 (cg-RX-API-DMAC7.html)
IL (1) IL304005A (cg-RX-API-DMAC7.html)
MX (1) MX2023007404A (cg-RX-API-DMAC7.html)
WO (2) WO2022134033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
WO2026132432A1 (en) 2024-12-20 2026-06-25 Curia Spain, S.A.U. Relacorilant crystalline forms

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1270488A (en) 1983-09-26 1990-06-19 John M. Schaus Pyrazole-ring alkylated pyrazoloquinolines and intermediates
GB8828669D0 (en) 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
DE69430373T2 (de) 1993-08-06 2002-12-12 Smithkline Beecham S.P.A., Baranzate Di Bollate Hydroisochinolinderivate
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
JP4498602B2 (ja) 1998-03-10 2010-07-07 リサーチ・トライアングル・インスティチュート 新規なオピエート化合物、その調製法及び使用法
US6166013A (en) 1998-07-30 2000-12-26 Abbott Laboratories Glucocortiocoid-selective agents
AU2620600A (en) 1999-01-21 2000-08-07 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
GB0010683D0 (en) 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
AU2002355929A1 (en) 2001-07-17 2003-03-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
CN1547473A (zh) 2001-07-23 2004-11-17 �Ƹ��� 预防由抗精神病药物引起的体重增加的方法
ATE411013T1 (de) 2001-08-31 2008-10-15 Corcept Therapeutics Inc Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom
CA2473886C (en) 2002-01-22 2012-08-21 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1534299A4 (en) 2002-07-02 2007-04-11 Corcept Therapeutics Inc METHOD FOR TREATING PSYCHOSIS IN CONNECTION WITH INTERFERON-ALPHA THERAPY
AU2003270783C1 (en) 2002-09-20 2010-05-20 Merck Sharp & Dohme Corp. Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
AU2004208842B2 (en) 2003-02-04 2009-05-28 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of postpartum psychosis
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1660081A1 (en) 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
CA2552419C (en) 2004-01-09 2013-04-23 Corcept Therapeutics, Inc. Azadecalin glucocorticoid receptor modulators
EP1723174A1 (en) 2004-02-26 2006-11-22 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health A novel modulator of glucocorticoid receptor activities
JP4931794B2 (ja) 2004-03-09 2012-05-16 コーセプト セラピューティクス, インコーポレイテッド 縮合環アザデカリン糖質コルチコイド受容体モジュレーター
US7576076B2 (en) 2004-07-02 2009-08-18 Corcept Therapeutics, Inc. Modified pyrimidine glucocorticoid receptor modulators
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7640389B2 (en) 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2009064738A2 (en) 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
US20120022121A1 (en) 2007-11-29 2012-01-26 Dalton James T Indoles, derivatives and analogs thereof and uses therefor
US20090156672A1 (en) 2007-12-17 2009-06-18 Northwestern University Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
US20110166115A1 (en) 2008-07-01 2011-07-07 Corcept Therapeutics, Inc. Use of mifepristone for the treatment of amyotrophic lateral sclerosis
US20100135956A1 (en) 2008-11-21 2010-06-03 Auspex Pharmaceuticals, Inc. Steroid modulators of progesterone receptor and/or glucocorticoid receptor
AU2010247766B2 (en) 2009-05-12 2015-05-21 Corcept Therapeutics, Inc. Solid forms and process for preparing
US9068185B2 (en) 2010-03-12 2015-06-30 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
BR112013004322A2 (pt) 2010-08-27 2016-06-21 Corcept Therapeutics Inc moduladores de azadecalin fundidos com piridil-aminas
US8658128B2 (en) 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
MX370976B (es) 2011-11-11 2020-01-10 Gilead Apollo Llc Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos.
ES2991315T3 (es) 2012-02-24 2024-12-03 Univ Chicago Métodos y composiciones relacionados con el antagonismo del receptor de glucocorticoides y con el cáncer de próstata
WO2013130420A1 (en) 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
NZ701469A (en) * 2012-05-25 2017-06-30 Corcept Therapeutics Inc Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
ES2943542T3 (es) 2013-11-25 2023-06-14 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
US10532150B2 (en) 2014-07-21 2020-01-14 Medtronic Minimed, Inc. Smart connection interface
EP3006453A1 (en) 2014-10-08 2016-04-13 Cosmo Technologies Ltd. 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP3233916A4 (en) 2014-12-19 2018-06-06 Alder Biopharmaceuticals, Inc. Humanized anti-acth antibodies and use thereof
JP6821582B2 (ja) 2015-03-02 2021-01-27 コーセプト セラピューティクス, インコーポレイテッド Acth分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
US20180064679A1 (en) 2015-03-05 2018-03-08 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
US9598459B2 (en) 2015-08-03 2017-03-21 Pop Test Oncology Llc Pharmaceutical compositions and methods
MX383318B (es) 2015-08-13 2025-03-13 Corcept Therapeutics Inc Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
AU2017228329B2 (en) * 2016-03-01 2021-03-11 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
PH12017000049B1 (en) 2017-02-20 2018-08-29 Peter S Heilveil Aerial cable spacer
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
CN113194931B (zh) 2018-12-19 2023-11-10 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
NZ778399A (en) * 2019-02-22 2024-11-29 Corcept Therapeutics Inc Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
JP2023515781A (ja) 2020-02-10 2023-04-14 コーセプト セラピューティクス, インコーポレイテッド 選択的グルココルチコイド受容体モジュレーターを使用して抗腫瘍応答を刺激する方法
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
AU2023301396A1 (en) 2022-06-28 2024-12-12 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators

Also Published As

Publication number Publication date
JP2024501956A (ja) 2024-01-17
AU2025203341A1 (en) 2025-05-29
KR20230124985A (ko) 2023-08-28
AU2025203341B2 (en) 2026-03-05
AU2021410756A1 (en) 2023-07-06
MX2023007404A (es) 2023-08-21
WO2022140600A1 (en) 2022-06-30
CA3202354A1 (en) 2022-06-30
US20220227753A1 (en) 2022-07-21
US12152028B2 (en) 2024-11-26
CN116867780A (zh) 2023-10-10
AU2021410756B2 (en) 2025-02-13
WO2022134033A1 (en) 2022-06-30
EP4267577A4 (en) 2024-11-27
US20250145620A1 (en) 2025-05-08
JP7720914B2 (ja) 2025-08-08
AU2021410756A9 (en) 2024-09-12
EP4267577A1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
IL297839A (en) Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
US20250145620A1 (en) Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
IL310699B1 (en) Thr-beta receptor agonist compound and preparation method and use thereof
IL294237A (en) Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator
IL294666A (en) A salt of a derivative compound of aminopyridine, its crystalline form and a process for its preparation
IL282163B1 (en) A pharmaceutical preparation for oral administration containing an aminopyrimidine derivative or a salt thereof
WO1997019059A1 (en) Novel substituted aryl compounds useful as modulators of acetylcholine receptors
IL297840A (en) Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
US20230416250A1 (en) Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN118660879A (zh) 双环吲哚糖皮质激素受体拮抗剂
WO2005051382A1 (ja) 脂質低下作用増強剤